In view of the limited predictive value of baseline plasma EBV DNA level, PD-L1 expression level, and Tumor mutational burden (TMB) in R/M-NPC, it is of great interest to find novel biomarkers to predict the efficacy of immunochemotherapy. This evidence concerns the gene CD274 and neoplasm.